Gerald J. Wroblewski
Profile
Gerald J.
Wroblewski served as Vice President-Operations at MacuSight, Inc., Senior Vice President-Operations at iScience Interventional Corp., Executive Vice President-Operations at Oculex Pharmaceuticals, Inc., and Chief Operations Officer at Otonomy, Inc. He holds an MBA from The California State University and an undergraduate degree from California Polytechnic State University.
Former positions of Gerald J. Wroblewski
| Companies | Position | End |
|---|---|---|
| OTONOMY | Chief Operating Officer | 2014-02-24 |
MacuSight, Inc.
 MacuSight, Inc. Pharmaceuticals: MajorHealth Technology MacuSight, Inc. develops and manufactures pharmaceuticals products. The firm engages in developing therapeutics for the treatment of severe ocular diseases and conditions. It offers sirolimus, a therapeutic for the treatment and prevention of wet age-related macular degeneration, as well as for the treatment of diabetic macular edema; and related compounds and other select therapeutics in the eye, as well as minimally-invasive ocular formulations. The company was founded in 2003 and is headquartered in Union City, CA. | Chief Operating Officer | - |
Oculex Pharmaceuticals, Inc.
 Oculex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Oculex Pharmaceuticals, Inc. manufactures and develops drugs. The company focuses on developing and manufacturing novel drug delivery systems that resolve the problems associated with treatment of inflammation following cataract surgery and diseases of the eye. It is located in Sunnyvale, CA. | Chief Operating Officer | - |
iScience Interventional Corp.
 iScience Interventional Corp. Medical/Nursing ServicesHealth Services iScience Interventional Corp. discovers and develops microcatheter and imaging technologies that enable ophthalmologists to deliver site-specific ocular therapies. It encompasses microcatheter-based therapies designed to access anatomical structures within the eye to aspirate ocular fluids or deliver sterile ophthalmic solutions to the eye. The firm addresses the previously unmet need for treatment of sight-threatening diseases with the innovative, minimally invasive iCath™ procedures. The company was founded by Michael F. Nash and Stan Conston in 1999 and is headquartered in Menlo Park, CA. | Chief Operating Officer | - |
Training of Gerald J. Wroblewski
| California Polytechnic State University (San Luis Obispo) | Undergraduate Degree |
| The California State University | Masters Business Admin |
Experiences
Positions held
Linked companies
| Private companies | 4 |
|---|---|
iScience Interventional Corp.
iScience Interventional Corp. Medical/Nursing ServicesHealth Services iScience Interventional Corp. discovers and develops microcatheter and imaging technologies that enable ophthalmologists to deliver site-specific ocular therapies. It encompasses microcatheter-based therapies designed to access anatomical structures within the eye to aspirate ocular fluids or deliver sterile ophthalmic solutions to the eye. The firm addresses the previously unmet need for treatment of sight-threatening diseases with the innovative, minimally invasive iCath™ procedures. The company was founded by Michael F. Nash and Stan Conston in 1999 and is headquartered in Menlo Park, CA. | Health Services |
MacuSight, Inc.
MacuSight, Inc. Pharmaceuticals: MajorHealth Technology MacuSight, Inc. develops and manufactures pharmaceuticals products. The firm engages in developing therapeutics for the treatment of severe ocular diseases and conditions. It offers sirolimus, a therapeutic for the treatment and prevention of wet age-related macular degeneration, as well as for the treatment of diabetic macular edema; and related compounds and other select therapeutics in the eye, as well as minimally-invasive ocular formulations. The company was founded in 2003 and is headquartered in Union City, CA. | Health Technology |
Oculex Pharmaceuticals, Inc.
Oculex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Oculex Pharmaceuticals, Inc. manufactures and develops drugs. The company focuses on developing and manufacturing novel drug delivery systems that resolve the problems associated with treatment of inflammation following cataract surgery and diseases of the eye. It is located in Sunnyvale, CA. | Health Technology |
Otonomy, Inc.
 Otonomy, Inc. BiotechnologyHealth Technology Otonomy, Inc. operates as a biopharmaceutical company. engages in the development of therapeutics for neurotology. The firm’s product pipeline includes OTIVIDEX (dexamethasone) Meniere's disease, OTIPRIO (ciprofloxacin otic suspension) acute otitis media with tubes (AOMT), OTO-313 (gacyclidine) tinnitus, OTO-413 (BDNF) hidden hearing Loss, OTO-510 (otoprotectant) prevent CIHL, OTO-6XX (hair cell regeneration) severe hearing loss. It operates under the Otiprio brand. The company was founded by Jay B. Lichter, Jeffrey Harris, Rick Friedman, and Allen F. Ryan on May 6, 2008 and is headquartered in San Diego, CA. | Health Technology |
- Stock Market
- Insiders
- Gerald J. Wroblewski
